Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non-small-cell lung cancer (NSCLC) but have not been tested in resectable NSCLC, a condition in which little progress has been made during the past decade. METHODS: In this pilot study, we administered two preoperative doses of PD-1 inhibitor nivolumab in adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC. Nivolumab (at a dose of 3 mg per kilogram of body weight) was administered intravenously every 2 weeks, with surgery planned approximately 4 weeks after the first dose. The primary end points of the study were safety and feasibility. We also evaluated the tumor pathological response, expression of programmed death ligand 1 (PD-L1), mutational burden, and mutation-associated, neoantigen-specific T-cell responses. RESULTS: Neoadjuvant nivolumab had an acceptable side-effect profile and was not associated with delays in surgery. Of the 21 tumors that were removed, 20 were completely resected. A major pathological response occurred in 9 of 20 resected tumors (45%). Responses occurred in both PD-L1-positive and PD-L1-negative tumors. There was a significant correlation between the pathological response and the pretreatment tumor mutational burden. The number of T-cell clones that were found in both the tumor and peripheral blood increased systemically after PD-1 blockade in eight of nine patients who were evaluated. Mutation-associated, neoantigen-specific T-cell clones from a primary tumor with a complete response on pathological assessment rapidly expanded in peripheral blood at 2 to 4 weeks after treatment; some of these clones were not detected before the administration of nivolumab. CONCLUSIONS: Neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors. The tumor mutational burden was predictive of the pathological response to PD-1 blockade. Treatment induced expansion of mutation-associated, neoantigen-specific T-cell clones in peripheral blood. (Funded by Cancer Research Institute-Stand Up 2 Cancer and others; ClinicalTrials.gov number, NCT02259621 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies examining the clinical activity of single agent anti-PD-1/PD-L1 therapies in the neoadjuvant setting have reported MPR rates between 19% and 45% in patients with resectable NSCLC14–16.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some studies have found that high TCR diversity in peripheral blood and tumors prior to ICI therapy is predictive of effective treatment, others have pointed to ICI therapy-associated increases in TCR clonality, that is, enrichment of T cells with the same TCRs, as a sign of effective therapy (150, 157-161).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [160]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune checkpoint blockade (ICB), especially targeting the inhibitory receptor programmed cell death 1 (PD-1) expressed on CD8+ T cells, is a highly effective immunotherapy for various cancers.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“Similarly, studies of neoadjuvant immunotherapy in patients with resectable NSCLC reported responses irrespective of PD-L114,21,”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [14]
In the citing paper
“Clinical trials with ICT in the neoadjuvant setting have now demonstrated clinical benefit in multiple tumor types, including melanoma (173, 174), Merkel cell carcinoma (175), NSCLC (176), MMRdeficient colorectal cancer (177), urothelial carcinoma (21, 178), and breast cancer (179-181).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [176]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cited by
Items 801–900 of 1,000
Systematic Review of Neoadjuvant Immunotherapy for Patients With Non–Small Cell Lung Cancer
Cao, C. Q., Guo, A., Chen, C., Chakos, A., Bott, M. J., Yang, C. J., Zielinski, R., & Melfi, F. M. A. (2021) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2020.12.012 · Cited by 20
Remón, J., Menis, J., Lévy, A., Ruysscher, D. D., & Hendriks, L. E. L. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1065 · Cited by 19
“In contrast, when extrapolating data from early-stage NSCLC, the combination of chemotherapy and ICI results in the highest rate of major pathological response (31-33).”
Zhai, H., Li, W., Jiang, K., Zhi, Y., & Yang, Z. (2022) · Cancer Management and Research · doi:10.2147/cmar.s344343 · Cited by 21
“%) patients with stage IIIB NSCLC.”
InfluentialNeoadjuvant immunotherapy in patients with resectable non–small cell lung cancer
Broderick, S., & Bott, M. J. (2019) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.06.114 · Cited by 20
Self-citationCACA guidelines for holistic integrative management of lung cancer
Wang, J. (2024) · Holistic Integrative Oncology · doi:10.1007/s44178-024-00069-w · Cited by 23
“(2) Neoadjuvant immunotherapy: For operable stage I-IIIA LC, in the CheckMate-159 study, [27] nivolumab was adopted for neoadjuvant therapy and was associated with an MPR rate of 42.9%.”
InfluentialSurgery challenges and postoperative complications of lung cancer after neoadjuvant immunotherapy
Bai, G., Chen, X., Yue, P., Ji, Y., Bie, F., Liu, Y., Yang, Z., & Gao, S. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15297 · Cited by 20
Combinational CAR T-cell therapy for solid tumors: Requisites, rationales, and trials
Misawa, K., Bhat, H., Adusumilli, P. S., & Hou, Z. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108763 · Cited by 22
Intratumoral heterogeneity and immunotherapy resistance: clinical implications
Keenan, B. P., Yadav, M., Ansstas, G., Fabrizio, D. A., Murugesan, K., Montesion, M., Niyogi, D. G., Mellman, I., & Melero, I. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.1239 · Cited by 26
Stroh, G. R., Peikert, T., & Escalante, P. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02905-8 · Cited by 19
Ni, J., Huang, M., Zhang, L., Wu, N., Bai, C., Chen, L., Liang, J., Liu, Q., Wang, J., Wu, Y.-L., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13942 · Cited by 23
Self-citationCell-by-Cell: Unlocking Lung Cancer Pathogenesis
Sinjab, A. F., Rahal, Z., & Kadara, H. N. (2022) · Cancers · doi:10.3390/cancers14143424 · Cited by 23
Neoadjuvant therapy gains FDA approval in non-small cell lung cancer
Leal, T. A. B., & Ramalingam, S. S. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100691 · Cited by 19
Qu, R., Ye, F., Hu, S., Wang, B., Qin, S., Xiong, J., Fu, X., Li, L., & Cai, Y. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04289-3 · Cited by 19
“On the basis of encouraging results in several phase I/II clinical trials of neoadjuvant immunotherapy for patients with resectable NSCLC (Forde et al. 2018; Rusch et al. 2018; Sepesi et al. 2019), several clinical trials of neoadjuvant immunotherapy for early-stage lung cancer are underway including GGOLUAD in our ce…”
BackgroundInfluentialHan, Y., Zhang, Y., Tian, Y., Zhang, M., Cheng, X., Zhen, Q., Liu, J., Shang, Y., Zhao, Y., Si, H., et al. (2022) · Journal of Oncology · doi:10.1155/2022/9016296 · Cited by 21
“In the recently reported “NADIM” study of ICIs for the neoadjuvant therapy of NSCLC, the results were even more promising, with a disease control rate of 96%, showing once again the great application prospect and therapeutic potential of immunotherapy [21].”
Tumor-derived extracellular vesicles in the colorectal cancer immune environment and immunotherapy
Prakash, A., Gates, T. J., Zhao, X., Wangmo, D., & Subramanian, S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108332 · Cited by 23
Wang, X., Ling, X., Wang, C., Zhang, J., Yang, Y., Jiang, H., Xin, Y., Zhang, L., Liang, H., Fang, C., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03354-7 · Cited by 18
Self-citationNeoadjuvant Immunotherapy for Patients With Non–Small Cell Lung Cancer—Is a New Era Coming?
Zhang, B., Zhong, H., & Han, B. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.6898 · Cited by 18
Potential biomarkers for immunotherapy in non-small-cell lung cancer
Wang, X., Qiao, Z.-Y., Aramini, B., Lin, D. X., Li, X., & Fan, J. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10074-y · Cited by 22
“A rapid increase in mutation-associated, neoantigen-specific T cell clones from the main cancer in peripheral blood was detected after treatment, some of which were not detected at baseline levels [47].”
BackgroundParks, O. B., Eddens, T. J., Sojati, J., Lan, J., Zhang, Y., Oury, T. D., Ramsey, M. J., Erickson, J. J., Byersdorfer, C. A., & Williams, J. V. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00365-5 · Cited by 19
“Since HMPV causes an acute infection, we thought it unlikely that HMPV disease was causing classical CD8+ T cell exhaustion described in chronic infection [39] and cancer models [30, 40].”
BackgroundImmunotherapy for early-stage non-small cell lung cancer: A system review
Gao, J., Zhang, C., Wei, Z., & Ye, X. (2023) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_723_23 · Cited by 19
Xu, F., Zhu, H., Xiong, D., Wang, K., Dong, Y., Li, L., & Yuan, S. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15175 · Cited by 20
Preoperative Strategies for Locally Advanced Colon Cancer
Nair, K. G., Kamath, S. D., Chowattukunnel, N., & Krishnamurthi, S. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01184-6 · Cited by 19
Yi, C., Bian, D., Wang, J., Hu, S., Sun, L., Yan, Y., Wang, S., Shen, Z., Yu, H., Yang, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57184-z · Cited by 22
“The MPR for neoadjuvant immune checkpoint inhibitors (ICIs) monotherapy from CheckMate-159was 45%(9/20) 56 , andthe MPR of neoadjuvantICIsplus chemotherapy (LungMate-001)atstage IIIAwas 43%(13/30) 36 .”
Metabolic enzymes expressed by cancer cells impact the immune infiltrate
Stoll, G., Kremer, M., Bloy, N., Joseph, A., Castedo, M., Meurice, G., Klein, C., Galluzzi, L., Michels, J., & Kroemer, G. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1571389 · Cited by 20
Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
Chanzá, N. M., Tripathi, A., & Harshman, L. C. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0639-0 · Cited by 24
Targeted Therapies in Non-small-Cell Lung Cancer
Hill, A., Gupta, R. V., Zhao, D., Vankina, R., Amanam, I. U., & Salgia, R. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_1 · Cited by 20
Bernicker, E., & Quigley, E. M. M. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.016 · Cited by 20
Challenges to Randomized Trials in Adult and Congenital Cardiac and Thoracic Surgery
Gaudino, M. F. L., Chikwe, J., Bagiella, E., Fremes, S. E., Jones, D. R., Meyers, B. F., Newburger, J. W., Ohye, R. G., Sassalos, P., Wigle, D. A., et al. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2020.11.042 · Cited by 18
Self-citationAdvances in Adoptive Cell Therapy for Head and Neck Cancer
Norberg, S. M., & Hinrichs, C. S. (2021) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2021.05.001 · Cited by 22
“Awareness of the development of immune resistance, especially as cancers evolve over time and through multiple therapies, is driving a movement in oncology toward earlier application of immunotherapy including adoptive T-cell therapy.(25,26) A clinical trial at the NCI Genitourinary Malignancies Branch will test E7 TC…”
BackgroundImmunotherapy in head and neck squamous cell carcinoma: a narrative review
Sharon, S., & Bell, R. B. (2022) · Frontiers of Oral and Maxillofacial Medicine · doi:10.21037/fomm-21-48 · Cited by 19
“non-responders on a cellular level (46,47) and to examine the response to treatment and adjust it accordingly.”
BackgroundTang, X., Yang, J., Shi, A., Xiong, Y., Wen, M., Luo, Z.-L., Tian, H., Zheng, K., Liu, Y., Shu, C., et al. (2022) · Cancers · doi:10.3390/cancers14225610 · Cited by 19
Beattie, J., Yarmus, L. B., Wahidi, M. M., Rivera, M. P., Gilbert, C. R., Maldonado, F., Czarnecka, K., Argento, A. C., Chen, A. J., Herth, F. J. F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201712-2539pp · Cited by 19
Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer
Puri, S., Shafique, M. R., & Gray, J. E. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0556-7 · Cited by 19
Hyperprogression with immunotherapy: Is it real?
Popat, S. (2019) · Cancer · doi:10.1002/cncr.31997 · Cited by 20
“In addition, the advent of neoadjuvant CPI trials has clearly demonstrated a dissociation between radiological findings and tumor status, with several data sets now demonstrating radiologically stable changes but increasing necrosis associated with complete or nearly complete pathological responses on resection.(4) Im…”
BackgroundDelayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review
Ciner, A., Höchster, H. S., August, D. A., Carpizo, D. R., & Spencer, K. R. (2021) · Immunotherapy · doi:10.2217/imt-2020-0329 · Cited by 17
A Multi-Omics Network of a Seven-Gene Prognostic Signature for Non-Small Cell Lung Cancer
Ye, Q., Falatovich, B., Singh, S., Ivanov, A. V., Eubank, T. D., & Guo, N. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010219 · Cited by 18
“There was reported synergy between PD-1 blockade and CD27 stimulation for CD8+ T-cell driven anti-tumor immunity [62], indicating the therapeutic potential of CD27 in neoadjuvant PD-1 blockade in early-stage NSCLC [63].”
BackgroundmTOR Pathway Gene Mutations Predict Response to Immune Checkpoint Inhibitors in Multiple Cancers
Cheng, L., Wang, Y., Qiu, L., Chang, Y., Lu, H., Liu, C., Zhang, B., Zhou, Y., Bai, H., Xiong, L., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03436-1 · Cited by 19
“in neoadjuvant therapy [5] and frontline therapy [6] of advanced cancers.”
BackgroundLung Cancer Recurrence Risk Prediction through Integrated Deep Learning Evaluation
Huang, P., Illei, P. B., Franklin, W. A., Wu, P., Forde, P. M., Ashrafinia, S., Hu, C., Khan, H. A., Vadvala, H. V., Shih, I., et al. (2022) · Cancers · doi:10.3390/cancers14174150 · Cited by 20
Self-citationLiu, W. Y., Zhang, T., Zhang, Q., Li, L., & Xu, C. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02292-5 · Cited by 17
Yang, Z., Zhang, D., Sima, X., Fu, Y., Zeng, H., Hu, Z., Hou, J., Pan, Y., Zhang, Y., Zhou, Z., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109687 · Cited by 19
Du, X., Wen, S., Shi, R., Xia, J., Wang, R., Zhang, Y., Pan, B., Wu, X., Zhu, W., Feng, J., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10502-4 · Cited by 19
Wang, P., Zhang, Z., Zhang, S., Xing, Q., Zhao, Z., Lin, Q., Shen, L., Xia, Z., Li, F., & Zhu, B. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04696-0 · Cited by 19
Recent Advances in Perioperative Immunotherapies in Lung Cancer
Fukuda, S., Suda, K., Hamada, A., & Tsutani, Y. (2023) · Biomolecules · doi:10.3390/biom13091377 · Cited by 19
“In treatment of advanced-stage NSCLC, ICI combination therapies such as nivolumab plus the anti-CTLA-4 antibody ipilimumab showed superior efficacy over chemotherapy irrespective of the PD-L1 status (e.g., CheckMate 227) [35].”
BackgroundDrug resistance mechanism and reversal strategy in lung cancer immunotherapy
Xu, Y., Liu, Y., Ge, Y., Li, H., Zhang, Y., & Wang, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1230824 · Cited by 18
“According to clinical experience, preoperative immunotherapy can fight for the chance of surgery, and reduce the recurrence rate after surgery (Forde et al., 2018; Lee et al., 2019; Reuss et al., 2020).”
BackgroundLavaud, P., Bortolot, M., Zullo, L., O’Reilly, D., Naidoo, J., Mountzios, G., Mercier, O. M., Hendriks, L. E. L., & Remón, J. (2024) · Cancers · doi:10.3390/cancers16162779 · Cited by 18
“The pivotal phase II CheckMate 159 trial showed that just two cycles of neoadjuvant nivolumab in 21 patients with resectable stage IB-IIIA NSCLC yielded a 45% MPR, including 15% of pCR [41].”
BackgroundSelf-citationRosner, S., Connor, S. C., Sanber, K. S., ZAHURAK, M. L., Zhang, T., Gurumurthy, I., Zeng, Z., Presson, B., Singh, D., Rayes, R. F., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2983 · Cited by 21
Self-citationTherapeutic potential of targeting LAG-3 in cancer
Davar, D., Anderson, A. C., & Díaz-Padilla, I. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011652 · Cited by 18
Jiang, L., Huang, W., Liu, J., Harris, K. N., Yarmus, L. B., Shao, W., Chen, H., Liang, W., & He, J. (2019) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.07.095 · Cited by 18
Kris, M. G., Finn, C. F., Kordbacheh, T., Chaft, J. E., Luo, J., Tsao, A. S., & Swisher, S. G. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280807 · Cited by 17
Self-citationRole of inflammasome activation in tumor immunity triggered by immune checkpoint blockers
Segovia, M., Russo, S., Girotti, M. R., Rabinovich, G. A., & Hill, M. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13433 · Cited by 20
Franco, A. O., Calvo, V., Franco, F., Provencio, M., & Califano, R. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-546 · Cited by 18
Immunotherapy Combined with Metronomic Dosing: An Effective Approach for the Treatment of NSCLC
Skavatsou, E., Semitekolou, M., Morianos, I., Karampelas, T., Lougiakis, N., Xanthou, G., & Tamvakopoulos, C. (2021) · Cancers · doi:10.3390/cancers13081901 · Cited by 17
“The levels of the PD-1 inhibitory receptor on tumor-infiltrating T cells, along with those of its ligand, PD-L-1, on tumor and infiltrating myeloid cells are associated with responsiveness to ICI immunotherapies in NSCLC patients [27].”
BackgroundA prognostic immune risk score for diffuse large B‐cell lymphoma
Ma, S., Tian, X., Cai, J., Su, N., Yu, F., Zhang, Y., Wang, J., Gale, R. P., & Cai, Q. (2021) · British Journal of Haematology · doi:10.1111/bjh.17478 · Cited by 17
“The PD-1/PD-L1 inhibitor immunotherapy has shown effective anti-tumour activity in multiple tumour types.(19,20) However, except for primary mediastinal large B-cell lymphoma (PBMCL), the overall efficacy of PD-1/PD-L1 antibody on B-cell non-Hodgkin lymphoma is not satisfactory, and the treatment response rate is much…”
BackgroundSmith, A., Wali, A., Montes, A., Hadaki, M., Harrison‐Phipps, K., Karapanagiotou, E. M., & Billè, A. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26691 · Cited by 19
Catania, C., Muthusamy, B., Spitaleri, G., Signore, E. D., & Pennell, N. A. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.11.003 · Cited by 18
Synn, C., Kim, S. E., Lee, H. K., Kim, M. H., Kim, J. H., Lee, J. M., Jo, H.-N., Lee, W., Kim, D. K., Byeon, Y., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1364 · Cited by 20
Self-citationNeoantigen-Specific T Cells in Adoptive Cell Therapy
Tran, E. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000605 · Cited by 17
Expert consensus on perioperative treatment for non-small cell lung cancer
Duan, J., Tan, F., Bi, N., Chen, C., Chen, K., Cheng, Y., Chu, Q., Ge, D., Hu, J., Huang, Y., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-527 · Cited by 19
Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art
Laschtowitz, A., Roderburg, C., Tacke, F., & Mohr, R. U. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s347944 · Cited by 18
“In line, data from melanoma and lung cancer showed the superiority of peri- versus postoperative immunotherapy.(10,17) This concept has also been validated in animal models, where a preoperative PD-1 blockade led to improved survival and enhanced tumor-specific CD8+ T cell activation compared to postoperative PD-1 blo…”
ResultFoster, C. C., Rusthoven, C. G., Sher, D. J., Feldman, L. E., Pasquinelli, M. M., Spiotto, M. T., & Koshy, M. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.02.023 · Cited by 18
Liu, J., & Liu, Y. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152797 · Cited by 17
Zhigalova, E., Izosimova, A. V., Yuzhakova, D. V., Volchkova, L. N., Shagina, I. A., Turchaninova, M. A., Serebrovskaya, E. O., Вадимовна, З. Е., Chudakov, D. M., & Sharonov, G. V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00385 · Cited by 20
Real-World Pseudoprogression: an Uncommon Phenomenon
Reckamp, K. L. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.011 · Cited by 17
Zhai, W., Zhang, C., Duan, F., Xie, J., Dai, S., Lin, Y., Yan, Q., Rao, B.-Y., Li, L., Zhou, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1422717 · Cited by 20
Cheng, Y., Jiang, Z.-P., Chen, X., Lu, K.-Y., Liu, Z., & Shao, D. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005863 · Cited by 16
Boudoussier, A., Larrouture, I., Henrot, P., Veillon, R., Bardel, C., Chautemps, C., Caumont, C., Schilfarth, P., Duruisseaux, M., & Zysman, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-02251-0 · Cited by 16
“A reliable predictor of the anti-PD-(L)1 response has not been established (including PD-L1 expression and tumour mutation burden) 17–19 , although it would help physicians to identify patients with advanced lung cancer who are likely to be anti-PD-(L)1 responders.”
Geng, Z., Li, K., Mei, P., Gong, Z., Yan, R., Huang, Y., Zhang, C., Zhao, B., Lu, M., Yang, R., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002821 · Cited by 18
“The introduction of neoadjuvant immunotherapy has revolutionized the treatment paradigm for locally advanced lung cancer, significantly improving patient survival outcomes [ 2 ] .”
Laengle, J., Kuehrer, I., Kulu, A., Kabiljo, J., Ammon, D., Zirnbauer, R., Stift, A., Herbst, F., Dauser, B., Monschein, M., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.27769 · Cited by 16
Datta, R. R., Schran, S., Persa, O.-D., Aguilar, C., Thelen, M., Lehmann, J., Garcia-Marquez, M. A., Wennhold, K., Preugszat, E., Zentis, P., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3746 · Cited by 16
Chen, Z., John, J., & Wang, J. H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.995434 · Cited by 21
“HNSCCs (40) compared to other cancer types (44, 45).”
ResultXu, L., Shi, M., Wang, S., Li, M., Yin, W., Zhang, J., Zhu, J., Jiang, F., Xia, W., Qiu, N., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1009621 · Cited by 21
Self-citationImmunotherapy through the Lens of Non-Small Cell Lung Cancer
Stanley, R., Flanagan, S., Reilly, D. E. O., Kearney, E., Naidoo, J., & Dowling, C. M. (2023) · Cancers · doi:10.3390/cancers15112996 · Cited by 21
Self-citationD’Aiello, A., Stiles, B. M., Ohri, N., Levy, B. P., Cohen, P. R., & Halmos, B. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.02.004 · Cited by 19
Cao, L., Yu, Y., Li, Z., Wang, G.-R., Xiao, Y., Luo, H.-Y., Liu, B., & Bu, L. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17195-y · Cited by 18
“12 Uppaluri et al. first reported using pembrolizumab for neoadjuvant immunotherapy in resectable HNSCC, with only 2/36 patients achieving a major pathological response (MPR).”
Is cytoreductive nephrectomy relevant in the immunotherapy era?
Singla, N., Ghandour, R. A., & Margulis, V. (2019) · Current Opinion in Urology · doi:10.1097/mou.0000000000000659 · Cited by 16
“Furthermore, the oncologic benefits of combining surgical resection of the primary tumor with contemporary ICI agents have been shown for other malignancies, including lung cancer [25] and melanoma [26,27].”
BackgroundZhang, N., Wu, J., Yu, J., Zhu, H., Yang, M., & Li, R. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.10.016 · Cited by 16
LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence
Mitchell, K. G., Parra, E. R., Zhang, J., Nelson, D. B., Corsini, E. M., Villalobos, P. A., Moran, C. A., Skoulidis, F., Wistuba, I. I., Fujimoto, J., et al. (2020) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2020.03.114 · Cited by 18
Self-citationGentzler, R. D., Riley, D., & Martin, L. W. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00969-w · Cited by 16
Surgery for Locally Advanced and Oligometastatic Non–Small Cell Lung Cancer
Coster, J. N., & Groth, S. S. (2020) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2020.07.001 · Cited by 19
Kawana, S., Saito, R., Miki, Y., Kimura, Y., Abe, J., Sato, I., Endo, M., Sugawara, S., & Sasano, H. (2020) · Cancer Medicine · doi:10.1002/cam4.3639 · Cited by 17
Yang, H., Wang, Y., Jia, Z., Wang, Y., Yang, X., Wu, P., Song, Y., Xu, H., Gu, D., Chen, R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.537735 · Cited by 17
“Programmed death ligand 1, an effective biomarker for the prediction efficacy of immunotherapy in patients with advanced lung cancer, has no correlation with the efficacy of neoadjuvant or adjuvant immunotherapy in earlystage disease, indicating immunoheterogeneity between advanced and early-stage populations (44, 45).”
BackgroundCurative-Intent Treatment with Durvalumab in Early-Stage Cancers
Melillo, G., Chand, V. K., Yovine, A. J., Gupta, A. K., & Massacesi, C. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01675-0 · Cited by 18
New developments in locally advanced nonsmall cell lung cancer
Huber, R. M., Kauffmann-Guerrero, D. E., Hoffmann, H., & Flentje, M. P. (2021) · European Respiratory Review · doi:10.1183/16000617.0227-2020 · Cited by 16
Anand, A. C., & Acharya, S. K. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.04.003 · Cited by 16
Li, X., Yu, Z., & Li, S. (2021) · Materials & Design · doi:10.1016/j.matdes.2021.109958 · Cited by 17
Yang, Q., Wu, D., Wang, J., Ba, L., Tian, C., Liu, Y., Hu, Y., & Liu, L. (2021) · Scientific Reports · doi:10.1038/s41598-021-92115-0 · Cited by 20
Ge, S., & Huang, C. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1664 · Cited by 17
Systemic Immune Dysregulation Correlates With Clinical Features of Early Non-Small Cell Lung Cancer
Hao, Z., Lin, M., Du, F., Xin, Z., Wu, D., Yu, Q., Wu, Y., Zhu, Z., Li, W., Chen, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.754138 · Cited by 20
“As mentioned before, a higher pathological response rate in neoadjuvant therapy also underlines the significance of the systemic immune state of patients treated with immune checkpoint blockade of early NSCLC (27, 38).”
BackgroundFabrication of human serum albumin–imprinted photothermal nanoparticles for enhanced immunotherapy
Ma, J., Zhang, Y., Sun, H., Ding, P., & Chen, D. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb00396a · Cited by 16
Chen, S., Tian, D., Petersen, L., Cao, S., Quinn, Z., Kan, J., Zheng, M., Mao, W., & Wan, Y. (2022) · BioMed Research International · doi:10.1155/2022/7440189 · Cited by 16
Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions
NIKE Group, Gallo, M., Guarnotta, V., de Cicco, F., Rubino, M., Faggiano, A., & Colao, A. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02839-w · Cited by 16
Induction Strategy for Locally Advanced Thymoma
Zhang, Y., Li, Z., Chen, Y., Tan, L., Zeng, Z., Ding, J., & Du, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.704220 · Cited by 20
What Is Neo? Chemoimmunotherapy in the Neoadjuvant Setting for Resectable Non–Small-Cell Lung Cancer
Shu, C. A., & Cascone, T. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01446 · Cited by 17
Hughes, E., Lauder, S. N., Smart, K., Bloom, A., Scott, J., Jones, E., Somerville, M., Browne, M., Blainey, A., Godkin, A., et al. (2020) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02603-x · Cited by 15
Niknafs, N., Najjar, M., Dennehy, C., Stouras, I., & Anagnostou, V. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0824 · Cited by 22
Self-citationPan, G.-Q., Yan, Y., Li, R., Chen, X., Zhang, S.-P., Qu, Y., Dong, R., Zhou, Y. J., Zhang, T.-S., Chen, Z.-Q., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156304 · Cited by 19
Role of immunotherapy in stage IIIA non-small cell lung cancer: a narrative review
Calvo, V., Sierra‐Rodero, B., Cruz‐Bermúdez, A., & Provencio, M. (2021) · Current Challenges in Thoracic Surgery · doi:10.21037/ccts-20-82 · Cited by 15
“Both processes trigger a powerful systemic antitumor immune response and the generation of memory T-cells that may provide long-term protection (15-18).”
BackgroundMethodResultInfluentialRescue Surgery after Immunotherapy/Tyrosine Kinase Inhibitors for Initially Unresectable Lung Cancer
Galetta, D., de Marinis, F., & Spaggiari, L. (2022) · Cancers · doi:10.3390/cancers14112661 · Cited by 16
Neoadjuvant Immunotherapy in Oncogene-Positive Non-Small Cell Lung Cancer: A Multicenter Study
Zhao, Z.-R., Lin, Z., Shen, J., Xie, Z., & Jiang, L. (2022) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2022.11.035 · Cited by 15
Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
Peng, Y., Li, Z., Fu, Y., Pan, Y., Zeng, Y., Liu, J., Xiao, C., Zhang, Y., Su, Y., Li, G., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1011810 · Cited by 17
“In contrast, the local recurrence rate of stage IIB–IIIA patients is 12%–15%, with a distant recurrence rate of 40%–60% (15).”
BackgroundInfluential
Metadata
- Authors
- Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., Battafarano, R. J., Velez, M. J., Rekhtman, N., Olah, Z., Naidoo, J., Marrone, K. A., Verde, F., Guo, H., Zhang, J., Caushi, J. X., Chan, H. Y., Sidhom, J.-W., Scharpf, R. B., White, J., Gabrielson, E., Wang, H., Rosner, G. L., Rusch, V., Wolchok, J. D., Merghoub, T., Taube, J. M., Velculescu, V. E., Topalian, S. L., Brahmer, J. R., & Pardoll, D. M.
- Affiliations
- Johns Hopkins University (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Forde, Patrick M.
- Chaft, Jamie E.
- Smith, Kellie N.
- Anagnostou, Valsamo
- Cottrell, Tricia R.
- Hellmann, Matthew D.
- Zahurak, Marianna
- Yang, Stephen C.
- Jones, David R.
- Broderick, Stephen
- Velez, Moises J.
- Rekhtman, Natasha
- Naidoo, Jarushka
- Marrone, Kristen A.
- Verde, Franco
- Guo, Haidan
- Zhang, Jiajia
- Caushi, Justina X.
- Sidhom, John-William
- Scharpf, Robert B.
- White, James
- Wang, Hao
- Rosner, Gary L.
- Rusch, Valerie
- Wolchok, Jedd D.
- Merghoub, Taha
- Taube, Janis M.
- Velculescu, Victor E.
- Topalian, Suzanne L.
- Brahmer, Julie R.
- Pardoll, Drew M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-24
- Volume
- 378
- Issue
- 21
- Pages
- 1976-1986
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6223617
- OpenAlex
- W2798160602
- Cited by
- 2,099
- References
- 33
- Citations by year
- 2026: 123 · 2025: 181 · 2024: 241 · 2023: 304 · 2022: 304 · 2021: 342 · 2020: 279 · 2019: 214 · 2018: 110
- FWCI
- 89.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- International Association for the Study of Lung Cancer
- LUNGevity Foundation
- MacMillan Foundation
- Lung Cancer Foundation of America
- National Cancer Institute (CA006973, CA121113, CA180950, CA193145, P30 CA006973, P30 CA008748, R01 CA142779, T32 CA193145)
- ECOG-ACRIN
- Commonwealth Foundation
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Bristol-Myers Squibb
- Bloomberg–Kimmel Institute for Cancer Immunotherapy
- Stand Up To Cancer (SU2C-AACR-DT1012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- neoadjuvant immunotherapy, anti-PD-1 therapy, nivolumab, resectable non-small cell lung cancer, early-stage lung cancer, pathological response, PD-L1 expression, tumor mutational burden, predictive biomarkers, treatment safety and feasibility
- MeSH terms
- Nivolumab, Adenocarcinoma, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Biopsy, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Pilot Projects, Neoadjuvant Therapy, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.